## (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

# (19) World Intellectual Property Organization International Bureau

Organization
emational Bureau





(43) International Publication Date 8 July 2004 (08.07.2004) P

**PCT** 

(10) International Publication Number WO 2004/056871 A2

(51) International Patent Classification<sup>7</sup>:

C07K 14/81

(21) International Application Number:

PCT/EP2003/014654

(22) International Filing Date:

19 December 2003 (19.12.2003)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data: 02028465.9

19 December 2002 (19.12.2002) EP

- (71) Applicant (for all designated States except US): IPF PHARMACEUTICALS [DE/DE]; Feodor-Lynen-Str. 31, 30625 Hannover (DE).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): ADERMANN, Knut [DE/DE]; Schleldenstrasse 5, 30177 Hannover (DE). KIRCHHOFF, Frank [DE/DE]; Schmiedgasse 21-3, 89077 Ulm (DE). MÜNCH, Jan [DE/DE]; Einsteinstr. 17-2, 89077 Ulm (DE). SCHULZ, Axel [DE/DE]; Schneiderberg 28, 30167 Hannover (DE).


- (74) Agent: MEYERS, Hans-Wilhelm; P.O. Box 10 22 41, 50462 Cologne (DE).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (regional): ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

#### Published:

 without international search report and to be republished upon receipt of that report

[Continued on next page]

### (54) Title: PEPTIDES AND THEIR USE FOR THE TREATMENT OF HIV INFECTIONS



(57) Abstract: The invention relates to peptides with biological activity against infection having the amino acid sequence  $Z_1$ -LE- $X_1$ -IP- $X_2$ - $X_3$ - $X_4$ -P- $X_5$ - $X_6$ - $X_7$ - $X_8$ - $X_9$ - $X_{10}$ -K- $X_{11}$ - $X_{12}$ - $X_{13}$ - $X_{14}$ - $X_{15}$ - $Z_2$ , wherein  $X_1$  is a lysine, alanine, or aspartic acid;  $X_2$  is a cysteine, methionine or isoleucine;  $X_3$  is a serine, cysteine, lysine or glycine;  $X_4$  is an isoleucine, alanine, phenylalanine or cysteine;  $X_5$  is a proline, D-proline or a substituted L-or D-proline;  $X_6$  is a cysteine or glutamic acid;  $X_7$  is an amino acid with a hydrophobic or an aromatic side chain or cysteine;  $X_8$  is an amino acid with a hydrophobic or an aromatic side chain or cysteine;  $X_9$  is an amino acid with an aromatic side chain;  $X_{10}$  is a glycine, alanine or asparagine;  $X_{11}$  is a proline, aspartic acid, octahydroindolyl-2-carboxylic acid or D-1,2, 3,4-tetrahydroisoquinoline-3-carboxylic acid;  $X_{12}$  is a phenylalanine, alanine, glycine, glutamic acid or D-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid;  $X_{13}$  is an amino acid with a hydrophobic or an aromatic side chain;  $X_{14}$  is an amino acid with a hydrophobic or an aromatic side chain;  $X_{15}$  is a phenylalanine or deletion;  $Z_1$  is NH<sub>2</sub> or a sequence of 1 to 10 amino acid residues;  $Z_2$  is COOH or a sequence of 1 to 10 amino acid residues; and peptides which are fragments and/or covalently linked oligomers and/or derivatives, especially amidated, alkylated, acylated, sulfated, pegylated, phosphorylated and/or glycosylated derivatives, and mutants thereof, and with the provisio that (a) if  $X_{12}$  is alanine, glycine, glutamic acid, or D-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid than  $X_{13}$ ,  $X_{14}$  and  $X_{15}$  are phenylalanine, valine and phenylalanine respectively; and/or (b) if  $X_{12}$  is phenylalanine, than  $X_{13}$ ,  $X_{14}$  and  $X_{15}$  are valine, phenylalanine and a deletion, respectively; and (c) that there are at maximum two cysteine residues in a peptide.

# WO 2004/056871 A2

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.